Aims: To evaluate adherence, persistence, glycaemic control and costs at 12-month follow-up for patients initiating dulaglutide versus liraglutide or exenatide once weekly.
| INTRODUCTION
In a recent consensus statement, the American Diabetes Association and European Association for the Study of Diabetes recommended a patient-centred glycaemic management approach for patients with type 2 diabetes (T2D). 1 Glucagon-like peptide-1 receptor agonists (GLP1RAs) are given increased emphasis in the treatment approach after metformin because of the low associated risk of hypoglycaemia, potential for weight loss, and proven cardiovascular effects for some of these agents. The consensus report also recommends considering GLP-1RAs
prior to insulin as a first injectable option for treatment intensification in asymptomatic patients with T2D not at glycaemic goal. including nausea, vomiting and diarrhoea. 2, 3 Currently, liraglutide is the only agent indicated for reduction of cardiovascular risk in patients with established cardiovascular disease. 4 In addition to differences in clinical profiles, these GLP-1RAs have substantial differences in dosing regimen, need/length of dose titration, and administration device features such as need for reconstitution, single-dose vs. multi-dose devices, needle handling, and needle size (Appendix S1, Table S1 ). These differences in profile of GLP-1RAs may play an important role in treatment adherence, persistence and eventually effectiveness.
Increased adherence to anti-hyperglycaemic medications is associated with better glycaemic control, fewer complications, and lower healthcare utilization. [5] [6] [7] The change in HbA1c with long-acting GLP1RAs in real-world settings is approximately half that observed in randomized clinical trials. 8 Approximately 75% of that gap is attributed to poor adherence. 8 Additionally a decrease in adherence may worsen long-term health outcomes and consequently increase associated healthcare costs. [9] [10] [11] A study conducted by Alatorre et al 12 showed that patients initiating treatment with dulaglutide had higher adherence and persistence compared with patients initiating treatment with liraglutide or exenatide once weekly at 6-month followup. In a comparative glycaemic effectiveness study also using 6 months' follow-up, Unni et al 13 reported no significant differences between exenatide once weekly, dulaglutide, and albiglutide in HbA1c change from baseline; however, published literature on longer-term treatment adherence and persistence with GLP-1RAs
and their impact on glycaemic effectiveness and healthcare costs is limited. Because treatment adherence remains a major challenge among patients with T2D, it is important to evaluate the long-term real-world treatment patterns, including adherence, persistence and discontinuation, along with comparative glycaemic effectiveness, among agents in this promising class.
The aim of the present retrospective observational study in a US real-world setting, therefore, was to compare adherence, persistence, glycaemic control and cost outcomes at 12-month follow-up among commercially insured patients with T2D initiating treatment with one of the three long-acting GLP-1RAs commonly used in the United
States at the time of the study: dulaglutide, liraglutide, or exenatide once-weekly pen. 
| MATERIALS AND METHODS

| Study design
| Patient population
Patients aged ≥18 years were assigned to one of the three cohorts based on the earliest fill date (index date) for one of the index GLP1RAs prescribed (dulaglutide, liraglutide or exenatide once weekly). available divided by the number of days in the observation period.
The start date of each new prescription fill was adjusted whenever the patient had overlapping days' supply from the previous fill. For this study, it was assumed that patients finished the supply of the preceding fill before starting the new supply. 16 Patients with PDC ≥80%
were considered adherent.
Persistence was calculated as the number of days of continuous therapy from the point of initiation until the end of 12 months' follow-up, allowing a maximum gap of 45 days between fills. 12 To determine the duration of continuous therapy, dates of early refills were adjusted to the day after finishing the supply from the previous fill. A patient with a gap between the run-out date of the previous fill and the next fill of >45 days was considered to have discontinued treatment. The index dose of GLP-1RA and the percentage of patients with second fills were also reported.
All-cause and diabetes-related healthcare costs were calculated as the sum of patient-paid and plan-paid costs. Diabetes-related medical costs were aggregated costs for any medical claims that had diagnosis codes for any diabetes type; diabetes-related pharmacy costs were summed costs for any pharmacy claims that had antidiabetic medication generic product identifier codes. The MAP was used for adherence, persistence and cost analyses. 
| Statistical analysis
All variables were summarized using descriptive statistics, with mean, SD and median used for continuous variables, and counts and percentages used for categorical variables. Differences in continuous variables were tested using t-tests or Wilcoxon rank sum tests; χ 2 tests were used for categorical variables. An α level of 0.05 was used to identify statistical significance. No adjustments for multiple comparisons were made in this study.
Because of the observational nature of the study and lack of randomization of patients into the three study cohorts, it was necessary to control for treatment selection bias that may impact outcome. The propensity-score method to control for potential differences in characteristics influencing treatment selection has been widely accepted. 17, 18 Propensity scores, defined as the probability of initiating dulaglutide (vs. initiating liraglutide or exenatide once weekly) given the baseline characteristics, were calculated using logistic regression.
Two separate propensity-score models were created for the MAP, one for each comparison (dulaglutide vs. liraglutide and dulaglutide vs. exenatide once weekly; see Table 1 footnote for list of covariates).
Nearest-neighbour 1:1 matching with calipers was used. The caliper width was set to 0.2 of the SD of the logit of the propensity score. Additionally, patients were matched exactly on prior use of non-index GLP1RAs at baseline. 19 Absolute standardized differences of <0.10 were considered to denote balance in baseline characteristics between the cohorts. 20 Separate propensity-score models were created for the HbA1c analyses, and patients were matched exactly on the HbA1c result categories (<53, 53 to <64, 64 to <75, and >75). All propensity-score matching was finalized before the outcome analyses were conducted.
Cost comparison was carried out using generalized linear model analysis with gamma distribution and log link function or t-tests.
Kaplan-Meier survival analysis was used to assess the predicted probability of persistence to index GLP-1RA agent at 12-month followup. Comparisons were carried out between cohorts using log-rank tests.
Hazard ratios for discontinuation were calculated using Cox proportional hazard models. Relative risk of discontinuation was also calculated.
3 | RESULTS
| Study population
Prior to propensity-score matching, the MAP 
| Main analysis population 3.2.1 | Demographics and clinical characteristics
Demographics, baseline clinical characteristics and antidiabetic drug utilization were evaluated for both the pre-matching (Appendix S1, Table S2 ) and post-matching MAP (Table 1 ). In the matched dulaglutide and liraglutide cohort, the mean age was 54 years and 52% were men. The matched dulaglutide and exenatide once-weekly cohort was similar, with a mean age of 54 years and~51% men. Demographics and clinical characteristics were balanced in the two matched cohorts (Table 1 ).
In the dulaglutide and liraglutide matched cohort,~87% of patients used an OAD at baseline, with slightly more than half having used at least two classes of OAD. Similar baseline characteristics were observed in the dulaglutide and exenatide once-weekly matched cohort.
| Adherence and persistence
In the dulaglutide and liraglutide matched cohorts, 1462 patients (Table 2 ). Similar trends in adherence and persistence results were observed at 6-month follow-up (Appendix S1, Table S3 ).
Cox proportional hazard models showed that patients initiating dulaglutide were significantly less likely to discontinue therapy than those initiating liraglutide or exenatide once weekly ( Figure 1A,B) . 
| Healthcare costs
At 12-month follow-up, patients using dulaglutide had lower diabetesrelated medical costs compared with those using liraglutide ($6077 vs. $7026; P = 0.001), and higher diabetes-related pharmacy costs ($10 097 vs. $9668; P = 0.025). The mean diabetes-related total costs for dulaglutide versus liraglutide were $16 174 and $16 694, respectively (P = 0.184; Appendix S1, Table S4A ).
Diabetes-related pharmacy costs were higher for dulaglutide than for exenatide once weekly ($9694 vs. $8827; P < 0.001).
Diabetes-related medical costs were slightly higher for dulaglutide ($6074) than for exenatide once weekly ($5787), although the difference was not statistically significant (P = 0.322). The mean diabetes-related total costs for dulaglutide versus exenatide once weekly was $15 768 and $14 615, respectively (P = 0.005; Appendix S1, Table S4B ).
| HbA1c analysis population 3.3.1 | Glycaemic control
The baseline demographic and clinical characteristics for the HAP were balanced after propensity-score matching (Appendix S1, Tables S5A,B In all cohorts, patients who were adherent at 12-month follow-up had a greater reduction in HbA1c levels than patients who were nonadherent. Furthermore, a higher percentage of patients who were adherent achieved the HbA1c target of <53 mmol/mol than patients who were non-adherent (Figure 2 ).
Similar trends in HbA1c results were observed at 6-month followup (Appendix S1, Figure S2 ) among a subset of the patients in the HAP with HbA1c results available at the 6-month follow-up.
| Cost associated with glycaemic control: subset of the HAP with complete pharmacy cost
The average diabetes-related total costs at 12-month follow-up per 1% HbA1c reduction were $13 988 and $19 779 for patients initiating dulaglutide versus liraglutide, respectively; and were $13 241 and $16 496 for dulaglutide initiators versus exenatide once-weekly initiators, respectively (Figure 3 ).
| DISCUSSION
The results of the present real-world analysis showed that patients with T2D initiating dulaglutide treatment had significantly higher adherence and persistence at 12-month follow-up than patients initiating either liraglutide or exenatide once weekly. The observed adherence rates were consistent with previously published research.
Previous US studies reported 6-month dulaglutide adherence rates of 54% to 57%, 12, 21 which are similar to the 6-month adherence rate reported in the present study (59%; Appendix S1, Table S3 ). Similarly, our observed 6-month adherence rates of 46% for liraglutide and 41%
for exenatide once weekly were within the ranges previously reported (ie, 29% to 48% for liraglutide 12, 19, [22] [23] [24] [25] and 29% to 51% for exenatide once weekly 12, 19, 23, 25 ). When limiting the comparison to prior studies reporting outcomes at 12 months, adherence rates in the present study were higher than those reported in the limited data for both liraglutide (29% to 34% 22, 23 ) and exenatide once weekly ( 29% 23 ).
It is worth noting that a higher proportion of patients who initiated liraglutide discontinued therapy than those who initiated dulaglutide during the initial 30-day treatment period, and the difference in probability of persistence between dulaglutide and liraglutide initiators plateaued after~90 days of treatment. By contrast, the difference in probability of persistence between dulaglutide and exenatide once weekly continued to separate over time. and long-term safety. 26, 27 In addition to efficacy and safety, patient preference plays a particularly important role in treatment adherence and persistence. A simple dosing regimen as well as an easy-to-use delivery device have been shown to improve adherence 28, 29 ; thus, the higher adherence rates associated with dulaglutide treatment, in addition to its effectiveness, may also be a function of patient preference for device characteristics, such as ease of use, convenient dosing and administration.
In the subset of patients with available HbA1c results, those initiating dulaglutide had a greater reduction in HbA1c from baseline. The
HbA1c results observed for dulaglutide initiators in the present study are consistent with those in the AWARD programme, ie, 0.7% to 1.6% for the 0.75-mg dose and 0.8% to 1.6% for the 1.5-mg dose. [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] In the AWARD-6 trial, dulaglutide 1.5 mg was non-inferior to liraglutide 1.8 mg, and both treatments lowered HbA1c by 1.4% from baseline at 26 weeks. 31 The slightly higher HbA1c reduction for dulaglutide compared with liraglutide initiators could be attributable to the higher adherence among dulaglutide initiators in the present real-world study.
Treatment adherence is a key component in achieving target glycaemic levels. Lack of patient adherence explains 75% of the efficacy gap in HbA1c reduction between clinical trial and real-world data. 8 The present study results show that, in all cohorts, adherent patients had a greater reduction in HbA1c compared with non-adherent patients, highlighting the importance of adherence in achieving glycaemic control.
Improved adherence might be a contributing factor to higher diabetes-related pharmacy costs, as demonstrated in the present and previous studies 40, 41 ; however, consistent with previous research, 40, 41 the higher pharmacy costs of dulaglutide were offset by lower diabetes-related medical costs compared with liraglutide. Even though the mean total costs for dulaglutide were similar to those for liraglutide and significantly higher than for exenatide once weekly, when accounting for the reduction in HbA1c, the all-cause and diabetesrelated 12-month follow-up cost per 1% reduction in HbA1c was the lowest for the dulaglutitide cohort.
Several limitations should be considered when interpreting these results. Propensity-score matching was used to reduce confounding of treatment selection by ensuring balance in measured baseline characteristics; however, as in other observational studies, the present study was limited by the potential for bias attributable to unmeasured confounders. Data were derived from medical and pharmacy claims, which may have contained undetected coding errors. Also, certain patient (such as duration of diabetes, weight, education, or patient out-of-pocket costs) and provider characteristics that may be associated with the outcomes of interest were unavailable for analysis.
Pharmacy claims indicate only that a prescription was filled; it is unknown whether patients used the medication as prescribed. 
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